Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease.
Adult
Aged
Diet Surveys
/ statistics & numerical data
Disease Progression
Feeding Behavior
/ physiology
Female
Humans
Liver
/ diagnostic imaging
Liver Cirrhosis
/ diagnosis
Male
Metabolic Syndrome
/ epidemiology
Middle Aged
Non-alcoholic Fatty Liver Disease
/ diagnosis
Nuts
Prevalence
Risk Factors
Severity of Illness Index
Sex Factors
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
10
2020
accepted:
10
12
2020
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
20
3
2021
Statut:
epublish
Résumé
Nut consumption has been associated with reduced inflammation, insulin resistance, and oxidative stress. However, the influence on the prevalence and severity of non-alcoholic fatty liver disease (NAFLD) has yet to be evaluated. 4655 subjects were included as part of a colorectal carcinoma screening program (SAKKOPI) between 07/2010 and 07/2019 and analyzed 2020. Patients were characterized using biochemical and metabolic parameters, as well as a detailed questionnaire on dietary habits. The diagnosis of NAFLD was established using abdominal ultrasound. Consumption of nuts was graded as: no consumption or <1 time/week, 1-6 times/week, 1 time/day and ≥2 times/day. Mean age was 58.5±9.8years with a mean BMI of 26.5±4.7kg/m2. 2058 (44.2%) patients suffered from the metabolic syndrome, 2407 (51.6%) had arterial hypertension, 2287 (49.1%) showed prediabetes/diabetes, 1854 (39.4%) had dyslipidemia and 1984 patients (43.5%) were diagnosed with NAFLD. Prevalence of metabolic syndrome (1219 [48.7%] vs. 605 [40.2%] vs. 189 [37.4%] vs. 45 [31.7%], p<0.001) and NALFD (1184 [48.1%] vs. 594 [40.7%] vs. 158 [31.7%] vs. 48 [34.0%], p<0.001). On multivariable logistic regression analysis adjusting for potential confounders and dietary patterns, nut consumption ≥1time/day was inversely associated with NAFLD in the overall cohort (adjusted Odds ratio[aOR]: 0.719 [95%CI:0.558-0.926], p = 0.011). However, following subgroup analysis, this inverse association was only confirmed in male patients (aOR: 0.589 [95%CI: 0.411-0.844], p = 0.004) but not in females (aOR: 0.886 [95%CI: 0.616-1.275], p = 0.515). Moreover, patients who consumed nuts 1-6 times/week had a significantly lower prevalence of advanced fibrosis (Fib-4 score >2.67: aOR: 0.551 [95%CI: 0.338-0.898], p = 0.017; Forns-Index >6.9: aOR: 0.585 [95%CI: 0.402-0.850], p = 0.005). Nut consumption might exert beneficial effects on the prevalence of NAFLD in males. The negative association with advanced fibrosis warrants further investigation.
Sections du résumé
BACKGROUND
Nut consumption has been associated with reduced inflammation, insulin resistance, and oxidative stress. However, the influence on the prevalence and severity of non-alcoholic fatty liver disease (NAFLD) has yet to be evaluated.
METHODS
4655 subjects were included as part of a colorectal carcinoma screening program (SAKKOPI) between 07/2010 and 07/2019 and analyzed 2020. Patients were characterized using biochemical and metabolic parameters, as well as a detailed questionnaire on dietary habits. The diagnosis of NAFLD was established using abdominal ultrasound. Consumption of nuts was graded as: no consumption or <1 time/week, 1-6 times/week, 1 time/day and ≥2 times/day.
RESULTS
Mean age was 58.5±9.8years with a mean BMI of 26.5±4.7kg/m2. 2058 (44.2%) patients suffered from the metabolic syndrome, 2407 (51.6%) had arterial hypertension, 2287 (49.1%) showed prediabetes/diabetes, 1854 (39.4%) had dyslipidemia and 1984 patients (43.5%) were diagnosed with NAFLD. Prevalence of metabolic syndrome (1219 [48.7%] vs. 605 [40.2%] vs. 189 [37.4%] vs. 45 [31.7%], p<0.001) and NALFD (1184 [48.1%] vs. 594 [40.7%] vs. 158 [31.7%] vs. 48 [34.0%], p<0.001). On multivariable logistic regression analysis adjusting for potential confounders and dietary patterns, nut consumption ≥1time/day was inversely associated with NAFLD in the overall cohort (adjusted Odds ratio[aOR]: 0.719 [95%CI:0.558-0.926], p = 0.011). However, following subgroup analysis, this inverse association was only confirmed in male patients (aOR: 0.589 [95%CI: 0.411-0.844], p = 0.004) but not in females (aOR: 0.886 [95%CI: 0.616-1.275], p = 0.515). Moreover, patients who consumed nuts 1-6 times/week had a significantly lower prevalence of advanced fibrosis (Fib-4 score >2.67: aOR: 0.551 [95%CI: 0.338-0.898], p = 0.017; Forns-Index >6.9: aOR: 0.585 [95%CI: 0.402-0.850], p = 0.005).
CONCLUSIONS
Nut consumption might exert beneficial effects on the prevalence of NAFLD in males. The negative association with advanced fibrosis warrants further investigation.
Identifiants
pubmed: 33382757
doi: 10.1371/journal.pone.0244514
pii: PONE-D-20-32391
pmc: PMC7774938
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244514Déclaration de conflit d'intérêts
All authors declare that they have no conflicts of interest regarding the submitted work. The following authors disclose conflicts of interests outside the submitted work: C.D. is a member of the scientific advisory board of SPAR Österreichische Warenhandels-AG. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
JAMA. 2002 Nov 27;288(20):2554-60
pubmed: 12444862
Nutrients. 2017 Apr 14;9(4):
pubmed: 28420094
Liver Int. 2019 Sep;39(9):1732-1741
pubmed: 31162803
Hepatology. 2007 Apr;45(4):846-54
pubmed: 17393509
Int J Epidemiol. 1997;26 Suppl 1:S59-70
pubmed: 9126534
J Nutr. 2015 Oct;145(10):2287-92
pubmed: 26269239
Am J Gastroenterol. 2010 Sep;105(9):1978-85
pubmed: 20407430
Aliment Pharmacol Ther. 2020 Apr;51(7):728-736
pubmed: 32043602
J Nutr. 2012 Jun;142(6):1009-18
pubmed: 22513989
Nutr Rev. 2015 Jun;73(6):335-47
pubmed: 26011909
Nutr Metab (Lond). 2018 Jun 22;15:46
pubmed: 29977320
BMJ Open. 2019 Sep 4;9(9):e028961
pubmed: 31488477
Eur J Nutr. 2019 Aug;58(5):1759-1769
pubmed: 29761318
Nutrients. 2010 Jul;2(7):652-82
pubmed: 22254047
Nat Commun. 2019 Aug 13;10(1):3651
pubmed: 31409784
J Intern Med. 2011 Jul;270(1):41-9
pubmed: 21414047
Asia Pac J Clin Nutr. 2010;19(1):117-23
pubmed: 20199996
Food Nutr Res. 2017 Mar 29;61(1):1305193
pubmed: 28469546
Lancet Gastroenterol Hepatol. 2018 Jul;3(7):509-517
pubmed: 29893235
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Eur J Nutr. 2019 Jun;58(4):1463-1473
pubmed: 29574608
J Hepatol. 2018 Jun;68(6):1239-1246
pubmed: 29571924
Nutrients. 2019 May 17;11(5):
pubmed: 31108934
Gastroenterology. 2020 Jan;158(1):200-214
pubmed: 31563624
Med Clin (Barc). 2017 May 23;148(10):435-443
pubmed: 28126231
Am J Epidemiol. 2013 Jul 1;178(1):38-45
pubmed: 23703888
J Clin Med. 2020 Apr 09;9(4):
pubmed: 32283679
Gastroenterology. 2016 Jun;150(8):1704-9
pubmed: 26826669
Ann Nutr Metab. 1999;43(4):195-204
pubmed: 10592368
Minerva Endocrinol. 2017 Jun;42(2):173-183
pubmed: 27834478
N Engl J Med. 2010 May 6;362(18):1675-85
pubmed: 20427778
Int J Epidemiol. 1997;26 Suppl 1:S71-81
pubmed: 9126535
J Gastroenterol Hepatol. 2014 Jun;29(6):1265-72
pubmed: 24955455
World J Hepatol. 2015 Jun 8;7(10):1325-36
pubmed: 26052378
Adv Ther. 2017 Jun;34(6):1291-1326
pubmed: 28526997
Liver Int. 2017 Jul;37(7):936-949
pubmed: 28371239
Hepatology. 2002 Oct;36(4 Pt 1):986-92
pubmed: 12297848
PLoS One. 2013;8(2):e57367
pubmed: 23460844
J Clin Endocrinol Metab. 2019 Dec 1;104(12):6325-6337
pubmed: 30977830
Metabolism. 2011 Apr;60(4):474-9
pubmed: 20580779
J Am Coll Nutr. 2019 Aug;38(6):499-505
pubmed: 30716015
Am J Clin Nutr. 2018 Aug 1;108(2):371-380
pubmed: 29955838
Am J Epidemiol. 2006 Feb 1;163(3):222-31
pubmed: 16357111
N Engl J Med. 2019 Jan 3;380(1):11-22
pubmed: 30415628
J Am Coll Cardiol. 2017 Nov 14;70(20):2519-2532
pubmed: 29145952
Nutrients. 2017 Dec 02;9(12):
pubmed: 29207471
Clin Nutr. 2009 Feb;28(1):10-4
pubmed: 18834651
Int J Mol Sci. 2019 Apr 03;20(7):
pubmed: 30987167
J Clin Invest. 2004 Jun;113(11):1582-8
pubmed: 15173884
Gastroenterology. 2008 Aug;135(2):680-8
pubmed: 18505688
Am J Gastroenterol. 2017 May;112(5):740-751
pubmed: 27725647
N Engl J Med. 1998 Apr 9;338(15):1042-50
pubmed: 9535670
Am J Clin Nutr. 2016 Sep;104(3):722-8
pubmed: 27465378
Clin Nutr. 2019 Dec;38(6):2552-2557
pubmed: 30573353
Nutr Metab Cardiovasc Dis. 2011 Jul;21(7):518-25
pubmed: 20219336
Transplantation. 2019 Jan;103(1):22-27
pubmed: 30335697
Crit Rev Food Sci Nutr. 2017 Sep 22;57(14):3154-3163
pubmed: 27224877
J Hepatol. 2017 Aug;67(2):339-348
pubmed: 28578837
J Clin Invest. 2017 Jan 3;127(1):55-64
pubmed: 28045404
Circulation. 2019 Sep 17;140(12):e673-e691
pubmed: 31422671